Tuesday, March 17, 2026

Intel Hit Hard as Trump Calls for Repeal of Semiconductor Subsidies

Trump's hints at repealing the semiconductor law caused Intel's stock to drop 2.44%, highlighting its reliance on government support.

How Aekyung Industry’s K-Bodycare Products Are Taking Over Walmart: What You Need to Know

Aekyung Industrial launches K-Body Care products in Walmart U.S., featuring LUVSCENT and SHOWER MATE lines for American consumers.

Apple’s $500 Billion Investment in U.S. Marks Largest Ever

Apple's $500 billion U.S. investment over four years boosts stock price and market cap, creating 20,000 jobs and enhancing manufacturing.

Jin Joong Hwang

Author's Latest

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

How SK Chemical’s Nose-R Soft Cap Stand Out in Allergy Treatment: A Deep Dive into the OTC Market

SK Chemicals partners with Kyung Nam Pharm to enhance Nose-R Soft Cap sales in pharmacies, boosting allergy treatment distribution.

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

Chinese Biotech’s Rise: What’s the Standard of Global Tech Trade?

Analysts at the JPMHC noted a shift in biotech, with firms resisting sales and China emerging as a tech transfer leader.

Revolutionary Cancer Treatment SJ-650: What Makes It a Game Changer in Oncology?

SillaJen's SJ-650 cancer treatment platform gains recognition with publication in Molecular Therapy, showcasing its innovative approach and efficacy.

Unlock Youthful Skin: A Comprehensive Guide to Elabie Premier Fillers Launched in Thailand

Humedics launches Elavie Premier HA fillers in Thailand, marking significant expansion in Southeast Asia with a successful symposium.

CKDB-501A vs. Botox: Can CKD BiO’s New Botulinum Toxin Compete in China’s Booming Market?

Jongkundang Bio has successfully completed Phase 3 trials in China's botulinum toxin market, signaling global expansion.

How SK Bioscience Plans to Dominate the Global Vaccine Market in 2026

SK Bioscience enhances its operational system with new COO and key appointments to boost global competitiveness and vaccine development.

Botox Faces New Challenger: Chong Kun Dang’s Toxin Shows Non-Inferiority in China Study

Chong Kun Dang's CKDB-501A shows non-inferiority to Botox in Phase 3 trials for treating glabellar lines, with promising safety data.

NK Cell Cancer Therapies Move Closer to Market as Matica BioLabs Partners With Ingenium

CHA Biotech's Matica BioLabs partners with Ingenium Therapeutics for NK cell therapy production, targeting cancer treatment advancements.

ABL206: First-in-Class Dual Antibody Drug Conjugate Approved for Clinical Trials in the U.S. – What This Means for Cancer Treatment

ABL Bio and Neok Bio received FDA approval for ABL206, a dual-antibody ADC, marking a key milestone in their clinical development efforts.

K-Bio Revolution: How Korean Biopharmaceuticals Are Conquering the Global Market in 2026

South Korea's pharmaceutical industry thrives with innovative drugs like botulinum toxins and cancer treatments, targeting global markets.

Samsung Bioepis Secures U.S. Approval for Pen-Style Stelara Biosimilar, Setting a Market First

Samsung Bioepis receives FDA approval for Epyztek, the first pre-filled pen for autoimmune treatments, enhancing patient convenience.

Chong Kun Dang Wins European Phase 1 Approval for Dupixent Biosimilar: Advancing CKD-706’s Global Development

Chong Kun Dang's CKD-706 biosimilar for Dupixent received Phase 1 trial approval in Europe, aiming to expand treatment options for inflammatory diseases.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.